Showing 2281-2290 of 2656 results for "".
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trialshttps://modernod.com/news/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/2479372/Dopavision announced the closing of a €12 million Series A financing round. The proceeds will be used to fund the clinical development of MyopiaX, the company’s lead product in childhood myopia, with the goal to demonstrate its safety and efficacy in clinical studies and advance this innova
- Ocuphire to Present at Multiple Ophthalmic Conferences in Julyhttps://modernod.com/news/ocuphire-to-present-at-multiple-ophthalmic-conferences-in-july/2479363/Ocuphire Pharma announced that Jay S. Pepose, MD, Medical Advisor and Board Director, will be presenting two papers on presbyopia and reversal of mydriasis (RM) at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting on July 23-27, 2021 and that Mina Sooch, CEO and
- Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreadshttps://modernod.com/news/pfizer-plans-to-seek-fda-nod-for-covid-19-booster-next-month-as-delta-spreads/2479354/Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report. The mRNA-based vaccine, partnered with BioNTech, is cur
- Belkin Laser Announces Corporate Name Change to Belkin Visionhttps://modernod.com/news/belkin-laser-announces-corporate-name-change-to-belkin-vision/2479352/Israel-based medical device company Belkin Laser announced that it will begin operating under the new name of Belkin Vision. The name change is a strategic decision that will better reflect the company’s capability to solve future ophthalmic challenges, according to a company stateme
- Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenseshttps://modernod.com/news/bausch-lomb-expands-parameters-for-bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses/2479319/Bausch + Lomb announced the US launch of expanded parameters for Bausch + Lomb ULTRA Multifocal for Astigmatism contact lenses. The expansion, which includes the addition of -2.25D and -2.75D cylinder power parameters, will be part of the company’s standard offering of the lens and will ext
- EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edemahttps://modernod.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human
- Retinal Consultants of San Antonio Joins Retina Consultants of Americahttps://modernod.com/news/retinal-consultants-of-san-antonio-joins-retina-consultants-of-america/2479269/Retinal Consultants of San Antonio has joined the Retina Consultants of America (RCA), the management services organization’s its 11th practice. The addition of Retinal Consultants of San Antonio bolsters RCA’s presence in Texas as they join forces with RCA’s existing partner pra
- Neurophth Therapeutics and Hopstem Biotechnology Partner to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for Ocular Diseaseshttps://modernod.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/Neurophth Biotechnology and Hopstem Biotechnology announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases. The partnership leverages Neurophth’s experience in global gene/cell therapy drugs development and understanding of ophthalmic di
- EyeTech Digital Systems Releases the EyeOn Open Eye-Tracking Platformhttps://modernod.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/EyeTech Digital Systems announced the release of its software ecosystem for the EyeOn family of eye-tracking tablets. Software-agnostic EyeOn devices support EyeTech’s applications as well as third-party applications, arming engineers and end users with the highest reliability and lowest in